LT2205720T - Kompozicijos išsėtinės sklerozės gydymui - Google Patents

Kompozicijos išsėtinės sklerozės gydymui

Info

Publication number
LT2205720T
LT2205720T LTEP08838676.8T LT08838676T LT2205720T LT 2205720 T LT2205720 T LT 2205720T LT 08838676 T LT08838676 T LT 08838676T LT 2205720 T LT2205720 T LT 2205720T
Authority
LT
Lithuania
Prior art keywords
compositions
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Application number
LTEP08838676.8T
Other languages
English (en)
Inventor
Arnaud Foussat
Original Assignee
Txcell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/873,623 external-priority patent/US20090104142A1/en
Application filed by Txcell filed Critical Txcell
Publication of LT2205720T publication Critical patent/LT2205720T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP08838676.8T 2007-10-17 2008-10-17 Kompozicijos išsėtinės sklerozės gydymui LT2205720T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301475A EP2050814A1 (en) 2007-10-17 2007-10-17 Compositions for treating multiple sclerosis
US11/873,623 US20090104142A1 (en) 2007-10-17 2007-10-17 Compositions for treating multiple sclerosis
PCT/EP2008/064066 WO2009050283A1 (en) 2007-10-17 2008-10-17 Compositions for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
LT2205720T true LT2205720T (lt) 2017-03-27

Family

ID=40089903

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP08838676.8T LT2205720T (lt) 2007-10-17 2008-10-17 Kompozicijos išsėtinės sklerozės gydymui

Country Status (18)

Country Link
US (2) US9517253B2 (lt)
EP (2) EP2050814A1 (lt)
JP (2) JP2011500645A (lt)
KR (1) KR20100074286A (lt)
CN (1) CN101842478B (lt)
AU (1) AU2008313694B2 (lt)
CA (1) CA2702634C (lt)
CY (1) CY1118710T1 (lt)
DK (1) DK2205720T3 (lt)
ES (1) ES2618583T3 (lt)
HR (1) HRP20170353T1 (lt)
HU (1) HUE032066T2 (lt)
LT (1) LT2205720T (lt)
PL (1) PL2205720T3 (lt)
PT (1) PT2205720T (lt)
RU (1) RU2492234C2 (lt)
SI (1) SI2205720T1 (lt)
WO (1) WO2009050283A1 (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429584A4 (en) * 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
WO2012156522A1 (en) * 2011-05-19 2012-11-22 Tigenix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
RU2600160C1 (ru) * 2015-08-07 2016-10-20 Юрий Леонидович Шевченко Способ лечения рассеянного склероза и других системных аутоиммунных заболеваний
CN105254765A (zh) * 2015-10-10 2016-01-20 江汉大学 重组蛋白MOG35-55-I-Abβ1-α1及其基因和应用
WO2018078112A1 (en) * 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
JP7122002B2 (ja) * 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2018188730A1 (en) 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases
CN112004924A (zh) 2018-04-18 2020-11-27 Ucl商务有限公司 增强treg细胞抑制特性的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008A (en) * 1845-04-22 Improvement w the manufacture of oil from resin
ATE189230T1 (de) 1991-05-31 2000-02-15 Connetics Corp T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
CA2445640A1 (en) 2001-03-23 2002-10-03 John Matsoukas Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1578199A2 (en) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP1677821B1 (en) * 2003-10-17 2013-02-27 Baylor College Of Medicine A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
CA2585462A1 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
ES2368152T3 (es) * 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.

Also Published As

Publication number Publication date
HRP20170353T1 (hr) 2017-05-05
CA2702634A1 (en) 2009-04-23
JP2011500645A (ja) 2011-01-06
EP2205720A1 (en) 2010-07-14
KR20100074286A (ko) 2010-07-01
WO2009050283A1 (en) 2009-04-23
CN101842478B (zh) 2014-04-02
EP2050814A1 (en) 2009-04-22
DK2205720T3 (en) 2017-03-20
US20100221219A1 (en) 2010-09-02
EP2205720B1 (en) 2016-12-14
PT2205720T (pt) 2017-03-13
AU2008313694B2 (en) 2015-03-26
CN101842478A (zh) 2010-09-22
ES2618583T3 (es) 2017-06-21
US20170042992A1 (en) 2017-02-16
AU2008313694A1 (en) 2009-04-23
CY1118710T1 (el) 2017-07-12
HUE032066T2 (en) 2017-09-28
PL2205720T3 (pl) 2017-06-30
JP2014221819A (ja) 2014-11-27
CA2702634C (en) 2017-06-13
RU2492234C2 (ru) 2013-09-10
SI2205720T1 (sl) 2017-04-26
US9517253B2 (en) 2016-12-13
RU2010119505A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
SI2137537T1 (sl) Sestavki in uporabe za zdravljenje multiple skleroze
SI2205720T1 (sl) Sestavki za zdravljenje multiple skleroze
ZA200908898B (en) Dentifruce compositions for treating xerostomia
EP2219637A4 (en) AVENANTHRAMIDE COMPOSITIONS
IL199656A0 (en) Tablet-in-tablet compositions
GB0724342D0 (en) Anitbacterial compositions
PL2478907T3 (pl) Kompozycje do leczenia nowotworu
GB0711683D0 (en) Compositions
GB0712024D0 (en) Compositions
EP2355660A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
IL248919A0 (en) Pediatric compounds for the treatment of multiple sclerosis
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
EP2127647A4 (en) COMPOSITION FOR INHIBITING MUSCLE DAMAGE
GB2447012B (en) Composition for combating epistaxis
GB0722030D0 (en) Compositions for treating tumours
GB0614058D0 (en) Treatment for multiple sclerosis
GB0700573D0 (en) Composition for treating liver conditions
GB0711689D0 (en) Compositions
GB0706047D0 (en) Anit-viral compositions
GB0712043D0 (en) Compositions
GB0711685D0 (en) Compositions
GB0723803D0 (en) Compositions
GB0703964D0 (en) Compositions
GB0713261D0 (en) Compositions
GB0700477D0 (en) Compositions